Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
- 12 June 2022
- journal article
- letter
- Published by Elsevier in European Journal of Cancer
- Vol. 171, 43
Abstract
No abstract availableThis publication has 1 reference indexed in Scilit: